Dr. Rian Dickstein, MD
Claim this profileChesapeake Urology Research Associates
Studies Bladder Cancer
Studies Cancer
8 reported clinical trials
10 drugs studied
Area of expertise
1Bladder Cancer
Stage II
Stage I
2Cancer
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Rian Dickstein, MD is currently running
CG0070
for Bladder Cancer
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC
Recruiting2 awards Phase 35 criteria
EG-70
for Bladder Cancer
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
Recruiting1 award Phase 1 & 29 criteria
More about Rian Dickstein, MD
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Rian Dickstein, MD has experience with
- UGN-102
- CG0070
- TURBT
- Pembrolizumab Injection
- Bladder Removal
- Medical Management
Breakdown of trials Rian Dickstein, MD has run
Bladder Cancer
Cancer
Transitional Cell Carcinoma
Urologic Cancers
Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rian Dickstein, MD specialize in?
Rian Dickstein, MD focuses on Bladder Cancer and Cancer. In particular, much of their work with Bladder Cancer has involved Stage II patients, or patients who are Stage I.
Is Rian Dickstein, MD currently recruiting for clinical trials?
Yes, Rian Dickstein, MD is currently recruiting for 4 clinical trials in Hanover Maryland. If you're interested in participating, you should apply.
Are there any treatments that Rian Dickstein, MD has studied deeply?
Yes, Rian Dickstein, MD has studied treatments such as UGN-102, CG0070, TURBT.
What is the best way to schedule an appointment with Rian Dickstein, MD?
Apply for one of the trials that Rian Dickstein, MD is conducting.
What is the office address of Rian Dickstein, MD?
The office of Rian Dickstein, MD is located at: Chesapeake Urology Research Associates, Hanover, Maryland 21076 United States. This is the address for their practice at the Chesapeake Urology Research Associates.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.